// App-Quantinova.ai

2136 : Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers

Researchers

Presenter

  • Ge Wei

Principal Investigators

  • Elena Ardini

  • Roopal Patel

  • Nicholas Cam

  • Jason Harris

  • Jean-Michel Vernier

  • Nanqun Zhu

  • Litain Yeh

  • Robert Shoemaker

  • Pratik Multani

  • Zachary Hornby

  • Robert Wild

  • Gary G. Li

Medical Centers

  • Ignyta, Inc, San Diego, CA

  • Nerviano Medical Sciences, Milan, Italy.

Locations

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Melanoma

  • Sarcoma

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • Neurotrophic Receptor Tyrosine Kinase 2

  • Neurotrophic tropomyosin receptor kinase

  • High affinity nerve growth factor receptor

  • Proto-oncogene tyrosine-protein kinase ROS

Drug/Treatment

  • Entrectinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved